{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Schedule+C&page=9", "query": { "intervention": "Schedule C", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 396, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Schedule+C&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Schedule+C&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T09:11:22.832Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03400254", "title": "Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Hydroxychloroquine (HCQ)", "type": "DRUG" }, { "name": "Gedatolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-02-26", "completion_date": "2019-11-12", "has_results": false, "last_update_posted_date": "2020-04-28", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03400254" }, { "nct_id": "NCT02206425", "title": "Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ascorbic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "PLD", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-09", "completion_date": "2018-03-06", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 12, "location_summary": "Bakersfield, California • Concord, California • Encinitas, California + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206425" }, { "nct_id": "NCT02358343", "title": "A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depression", "End Stage Renal Disease" ], "interventions": [ { "name": "Engagement Interview", "type": "BEHAVIORAL" }, { "name": "Cognitive Behavioral Therapy", "type": "BEHAVIORAL" }, { "name": "Antidepressant Drug Therapy", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 184, "start_date": "2015-03-23", "completion_date": "2017-12-15", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 3, "location_summary": "Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Dallas", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358343" }, { "nct_id": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RO7496353", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2023-10-02", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 3, "location_summary": "Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867121" }, { "nct_id": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Pinatuzumab Vedotin", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2012-09-27", "completion_date": "2019-02-07", "has_results": true, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 26, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01691898" }, { "nct_id": "NCT06958107", "title": "LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Non-Metastatic and Resectable", "type": "OTHER" }, { "name": "Metastatic and Un-resectable", "type": "OTHER" }, { "name": "No evidence of disease, under surveillance", "type": "OTHER" }, { "name": "ALT or WDLS", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 300, "start_date": "2025-08-21", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06958107" }, { "nct_id": "NCT01656252", "title": "Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Phase I- Cytarabine & Eltrombopag", "type": "DRUG" }, { "name": "Phase II- Sequence A", "type": "DRUG" }, { "name": "Phase II- Sequence B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2012-07", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 5, "location_summary": "Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more", "locations": [ { "city": "Worcester", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656252" }, { "nct_id": "NCT06247995", "title": "A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 20, "start_date": "2024-08-14", "completion_date": "2027-04-14", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 5, "location_summary": "Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247995" }, { "nct_id": "NCT04117022", "title": "Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes", "Diabetic Retinopathy" ], "interventions": [ { "name": "DVS supplementation", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "ZeaVision, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 45, "start_date": "2019-09-01", "completion_date": "2022-12-01", "has_results": false, "last_update_posted_date": "2021-04-23", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 2, "location_summary": "Pomona, California • Tahlequah, Oklahoma", "locations": [ { "city": "Pomona", "state": "California" }, { "city": "Tahlequah", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04117022" }, { "nct_id": "NCT04144738", "title": "Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening \"BLUE-C\"", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "mt-sDNA 2.0 screening test", "type": "DIAGNOSTIC_TEST" }, { "name": "FIT test", "type": "DIAGNOSTIC_TEST" }, { "name": "Colonoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "Exact Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 26758, "start_date": "2019-11-15", "completion_date": "2023-03-30", "has_results": false, "last_update_posted_date": "2023-09-01", "last_synced_at": "2026-10-21T09:11:22.832Z", "location_count": 195, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 161 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04144738" } ] }